No BP of significance has partnered or bought out an OTC penny stock in the last decade. They won't touch a company that is under SEC and DOJ investigation, shareholder lawsuit, alienated the FDA, is insolvent, in debt to vulture funds, etc. Wouldn't pass any due diligence.
CCR5 inhibition has been investigated by most BP and they have moved on to many other more attractive targets. Only Pfizer launched one and it was not very successful. Don't bet on a BP buyout of Cytodyn as an investment thesis -- just look who they attracted -- Vyera and American Regent (who has already walked away).
News 
Market Data 
Discover 
AI
